Mustang Bio Inc (MBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mustang Bio Inc (MBIO) has a cash flow conversion efficiency ratio of -0.128x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-967.00K) by net assets ($7.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Mustang Bio Inc market capitalisation for the company's overall valuation and market capitalisation.
Mustang Bio Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Mustang Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mustang Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mustang Bio Inc ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Mustang Bio Inc to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FW Thorpe PLC
LSE:TFW
|
0.081x |
|
Colipays Reunion SA
PA:MLCLP
|
N/A |
|
Health and Plant Protein Group Ltd
AU:HPP
|
-0.067x |
|
Thai Mui Corporation Public Company Limited
BK:THMUI
|
0.100x |
|
Knosys Ltd
AU:KNO
|
0.865x |
|
Ximen Mining Corp
V:XIM
|
0.086x |
|
Thrive Tribe Technologies Ltd
AU:1TT
|
-1.889x |
|
Marula Mining PLC
F:48U0
|
N/A |
Annual Cash Flow Conversion Efficiency for Mustang Bio Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Mustang Bio Inc from 2016 to 2025. View today's stock price for Mustang Bio Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.53 Million | $-5.26 Million | -0.552x | -118.75% |
| 2024-12-31 | $-3.87 Million | $-11.41 Million | 2.946x | +100.73% |
| 2023-12-31 | $123.00K | $-49.48 Million | -402.252x | -28506.97% |
| 2022-12-31 | $46.27 Million | $-65.07 Million | -1.406x | -194.50% |
| 2021-12-31 | $112.40 Million | $-53.67 Million | -0.477x | -25.94% |
| 2020-12-31 | $98.44 Million | $-37.32 Million | -0.379x | +41.69% |
| 2019-12-31 | $51.65 Million | $-33.58 Million | -0.650x | -22.96% |
| 2018-12-31 | $36.40 Million | $-19.24 Million | -0.529x | -144.33% |
| 2017-12-31 | $59.83 Million | $-12.95 Million | -0.216x | -27.23% |
| 2016-12-31 | $24.28 Million | $-4.13 Million | -0.170x | -- |
About Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB… Read more